VERU
Veru Inc.'s Enobosarm Shows Promise in Treating Obesity and Preserving Lean Mass
On August 10, 2026, Veru Inc. hosted its quarterly earnings call, where the company provided updates on its clinical development progress and financial highlights for the third quarter of fiscal year 2026. The main focus of the conference call was on the company's drug enobosarm, a selective androgen